Larimar Therapeutics, Inc. (NASDAQ:LRMR) Stock Has Average Target Price of $10.33

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) has been assigned an average rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $10.00.

Several equities analysts recently issued reports on LRMR shares. Leerink Partners initiated coverage on shares of Larimar Therapeutics in a report on Monday, September 14th. They set an “outperform” rating and a $13.00 price objective on the stock. Wall Street Zen downgraded shares of Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Finally, Wedbush set a $9.00 target price on Larimar Therapeutics in a research report on Monday.

Read Our Latest Research Report on Larimar Therapeutics

Larimar Therapeutics Stock Performance

NASDAQ LRMR opened at $3.00 on Friday. The company has a market capitalization of $311.64 million, a price-to-earnings ratio of -1.54 and a beta of 0.73. The company’s 50-day simple moving average is $2.92 and its two-hundred day simple moving average is $3.76. Larimar Therapeutics has a one year low of $1.91 and a one year high of $6.42.

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06. Equities analysts expect that Larimar Therapeutics will post -1.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Thomas Hamilton purchased 70,000 shares of Larimar Therapeutics stock in a transaction dated Thursday, November 12th. The stock was purchased at an average cost of $2.67 per share, with a total value of $186,900.00. Following the transaction, the director owned 70,000 shares in the company, valued at approximately $186,900. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO John B. Jr. Harlow purchased 17,800 shares of Larimar Therapeutics stock in a transaction dated Wednesday, November 11th. The stock was bought at an average cost of $2.80 per share, with a total value of $49,840.00. Following the completion of the transaction, the chief operating officer owned 67,800 shares in the company, valued at approximately $189,840. This represents a 35.60% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 140,810 shares of company stock valued at $381,955. 4.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Larimar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LRMR. Integrated Wealth Concepts LLC bought a new position in Larimar Therapeutics in the second quarter worth about $27,000. Pallas Capital Advisors LLC bought a new stake in shares of Larimar Therapeutics in the 2nd quarter valued at about $31,000. HB Wealth Management LLC bought a new stake in shares of Larimar Therapeutics in the 2nd quarter valued at about $49,000. The Manufacturers Life Insurance Company purchased a new position in shares of Larimar Therapeutics in the 2nd quarter worth approximately $60,000. Finally, Walleye Trading LLC purchased a new position in shares of Larimar Therapeutics in the 2nd quarter worth approximately $61,000. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Further Reading

Analyst Recommendations for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.